Search

Your search keyword '"Taylor, Walter R J"' showing total 257 results
Start Over Author "Taylor, Walter R J"
257 results on '"Taylor, Walter R J"'

1. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Author

Luvira, Viravarn, Schilling, William H. K., Jittamala, Podjanee, Watson, James A., Boyd, Simon, Siripoon, Tanaya, Ngamprasertchai, Thundon, Almeida, Pedro J., Ekkapongpisit, Maneerat, Cruz, Cintia, Callery, James J., Singh, Shivani, Tuntipaiboontana, Runch, Kruabkontho, Varaporn, Ngernseng, Thatsanun, Tubprasert, Jaruwan, Abdad, Mohammad Yazid, Keayarsa, Srisuda, Madmanee, Wanassanan, Aguiar, Renato S., Santos, Franciele M., Hanboonkunupakarn, Pongtorn, Hanboonkunupakarn, Borimas, Poovorawan, Kittiyod, Imwong, Mallika, Taylor, Walter R. J., Chotivanich, Vasin, Chotivanich, Kesinee, Pukrittayakamee, Sasithon, Dondorp, Arjen M., Day, Nicholas P. J., Teixeira, Mauro M., Piyaphanee, Watcharapong, Phumratanaprapin, Weerapong, and White, Nicholas J.

Published
2024
Full Text
View/download PDF

2. Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis

Author

Fadilah, Ihsan, Commons, Robert J., Chau, Nguyen Hoang, Chu, Cindy S., Day, Nicholas P. J., Koh, Gavin C. K. W., Green, Justin A., Lacerda, Marcus VG, Llanos-Cuentas, Alejandro, Nelwan, Erni J., Nosten, Francois, Pasaribu, Ayodhia Pitaloka, Sutanto, Inge, Taylor, Walter R. J., Thriemer, Kamala, Price, Ric N., White, Nicholas J., Baird, J. Kevin, and Watson, James A.

Subjects
Hemoglobin -- Measurement -- Health aspects, Diseases -- Relapse, Primaquine -- Dosage and administration -- Physiological aspects, Malaria -- Drug therapy, Biological sciences
Abstract

Background The 8-aminoquinolines, primaquine and tafenoquine, are the only available drugs for the radical cure of Plasmodium vivax hypnozoites. Previous evidence suggests that there is dose-dependent 8-aminoquinoline induced methaemoglobinaemia and that higher methaemoglobin concentrations are associated with a lower risk of P. vivax recurrence. We undertook a systematic review and individual patient data meta-analysis to examine the utility of methaemoglobin as a population-level surrogate endpoint for 8-aminoquinoline antihypnozoite activity to prevent P. vivax recurrence. Methods and findings We conducted a systematic search of Medline, Embase, Web of Science, and the Cochrane Library, from 1 January 2000 to 29 September 2022, inclusive, of prospective clinical efficacy studies of acute, uncomplicated P. vivax malaria mono-infections treated with radical curative doses of primaquine. The day 7 methaemoglobin concentration was the primary surrogate outcome of interest. The primary clinical outcome was the time to first P. vivax recurrence between day 7 and day 120 after enrolment. We used multivariable Cox proportional-hazards regression with site random-effects to characterise the time to first recurrence as a function of the day 7 methaemoglobin percentage (log base 2 transformed), adjusted for the partner schizonticidal drug, the primaquine regimen duration as a proxy for the total primaquine dose (mg base/kg), the daily primaquine dose (mg/kg), and other factors. The systematic review protocol was registered with PROSPERO (CRD42023345956). We identified 219 P. vivax efficacy studies, of which 8 provided relevant individual-level data from patients treated with primaquine; all were randomised, parallel arm clinical trials assessed as having low or moderate risk of bias. In the primary analysis data set, there were 1,747 patients with normal glucose-6-phosphate dehydrogenase (G6PD) activity enrolled from 24 study sites across 8 different countries (Indonesia, Brazil, Vietnam, Thailand, Peru, Colombia, Ethiopia, and India). We observed an increasing dose-response relationship between the daily weight-adjusted primaquine dose and day 7 methaemoglobin level. For a given primaquine dose regimen, an observed doubling in day 7 methaemoglobin percentage was associated with an estimated 30% reduction in the risk of P. vivax recurrence (adjusted hazard ratio = 0.70; 95% confidence interval [CI] [0.57, 0.86]; p = 0.0005). These pooled estimates were largely consistent across the study sites. Using day 7 methaemoglobin as a surrogate endpoint for recurrence would reduce required sample sizes by approximately 40%. Study limitations include the inability to distinguish between recrudescence, reinfection, and relapse in P. vivax recurrences. Conclusions For a given primaquine regimen, higher methaemoglobin on day 7 was associated with a reduced risk of P. vivax recurrence. Under our proposed causal model, this justifies the use of methaemoglobin as a population-level surrogate endpoint for primaquine antihypnozoite activity in patients with P. vivax malaria who have normal G6PD activity., Author(s): Ihsan Fadilah 1,2,*, Robert J. Commons 3,4,5, Nguyen Hoang Chau 6, Cindy S. Chu 2,7, Nicholas P. J. Day 2,8, Gavin C. K. W. Koh 9, Justin A. Green [...]

Published
2024
Full Text
View/download PDF

3. Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Author

Schilling, William H. K., Mukaka, Mavuto, Callery, James J., Llewelyn, Martin J., Cruz, Cintia V., Dhorda, Mehul, Ngernseng, Thatsanun, Waithira, Naomi, Ekkapongpisit, Maneerat, Watson, James A., Chandna, Arjun, Nelwan, Erni J., Hamers, Raph L., Etyang, Anthony, Beg, Mohammad Asim, Sow, Samba, Yavo, William, Allabi, Aurel Constant, Basnyat, Buddha, Sharma, Sanjib Kumar, Amofa-Sekyi, Modupe, Yonga, Paul, Adler, Amanda, Yuentrakul, Prayoon, Cope, Tanya, Thaipadungpanit, Janjira, Rienpradub, Panuvit, Imwong, Mallika, Abdad, Mohammad Yazid, Blacksell, Stuart D., Tarning, Joel, Goudjo, Frejus Faustin, Dossou, Ange D., Konaté-Touré, Abibatou, Assi, Serge-Brice, Ouffoué, Kra, Nasronudin, Nasronudin, Rachman, Brian Eka, Romadhon, Pradana Zaky, Dewanto, Didi Darmahadi, Heryana, Made Oka, Novi, Theresia, Pasaribu, Ayodhia Pitaloka, Mutiara, Mutiara, Nasution, Miranda Putri Rahayu, Khairunnisa, Khairunnisa, Dalimunthe, Fauzan Azima, Airlangga, Eka, Fahrezzy, Akmal, Subronto, Yanri, Ananda, Nur Rahmi, Rahardjani, Mutia, Rimainar, Atika, Lucinde, Ruth Khadembu, Timbwa, Molline, Onyango, Otieno Edwin, Agutu, Clara, Akech, Samuel, Hamaluba, Mainga, Kipyego, Jairus, Ngachi, Obadiah, Haidara, Fadima Cheick, Traoré, Oumar Y., Diarra, François, Khanal, Basudha, Dahal, Piyush, Shrestha, Suchita, Rijal, Samita, Kabore, Youssouf, Adehossi, Eric, Guindo, Ousmane, Qamar, Farah Naz, Kazi, Abdul Momin, Woodrow, Charles J., Laird, Steven, Cheeba, Maina, Ayles, Helen, Cheah, Phaik Yeong, Taylor, Walter R. J., Batty, Elizabeth M., Chotivanich, Kesinee, Pukrittayakamee, Sasithon, Phumratanaprapin, Weerapong, von Seidlein, Lorenz, Dondorp, Arjen, Day, Nicholas P. J., and White, Nicholas J.

Subjects
Hydroxychloroquine -- Testing, Chloroquine -- Testing, Biological sciences
Abstract

Background Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. Methods and findings Healthy adult participants from the healthcare setting, and later from the community, were enrolled in 26 centres in 11 countries to a double-blind, placebo-controlled, randomised trial of COVID-19 chemoprevention. HCQ was evaluated in Europe and Africa, and chloroquine (CQ) was evaluated in Asia, (both base equivalent of 155 mg once daily). The primary endpoint was symptomatic COVID-19, confirmed by PCR or seroconversion during the 3-month follow-up period. The secondary and tertiary endpoints were: asymptomatic laboratory-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; severity of COVID-19 symptoms; all-cause PCR-confirmed symptomatic acute respiratory illness (including SARS-CoV-2 infection); participant reported number of workdays lost; genetic and baseline biochemical markers associated with symptomatic COVID-19, respiratory illness and disease severity (not reported here); and health economic analyses of HCQ and CQ prophylaxis on costs and quality of life measures (not reported here). The primary and safety analyses were conducted in the intention-to-treat (ITT) population. Recruitment of 40,000 (20,000 HCQ arm, 20,000 CQ arm) participants was planned but was not possible because of protracted delays resulting from controversies over efficacy and adverse events with HCQ use, vaccine rollout in some countries, and other factors. Between 29 April 2020 and 10 March 2022, 4,652 participants (46% females) were enrolled (HCQ/CQ n = 2,320; placebo n = 2,332). The median (IQR) age was 29 (23 to 39) years. SARS-CoV-2 infections (symptomatic and asymptomatic) occurred in 1,071 (23%) participants. For the primary endpoint the incidence of symptomatic COVID-19 was 240/2,320 in the HCQ/CQ versus 284/2,332 in the placebo arms (risk ratio (RR) 0.85 [95% confidence interval, 0.72 to 1.00; p = 0.05]). For the secondary and tertiary outcomes asymptomatic SARS-CoV-2 infections occurred in 11.5% of HCQ/CQ recipients and 12.0% of placebo recipients: RR: 0.96 (95% CI, 0.82 to 1.12; p = 0.6). There were no differences in the severity of symptoms between the groups and no severe illnesses. HCQ/CQ chemoprevention was associated with fewer PCR-confirmed all-cause respiratory infections (predominantly SARS-CoV-2): RR 0.61 (95% CI, 0.42 to 0.88; p = 0.009) and fewer days lost to work because of illness: 104 days per 1,000 participants over 90 days (95% CI, 12 to 199 days; p < 0.001). The prespecified meta-analysis of all published pre-exposure RCTs indicates that HCQ/CQ prophylaxis provided a moderate protective benefit against symptomatic COVID-19: RR 0.80 (95% CI, 0.71 to 0.91). Both drugs were well tolerated with no drug-related serious adverse events (SAEs). Study limitations include the smaller than planned study size, the relatively low number of PCR-confirmed infections, and the lower comparative accuracy of serology endpoints (in particular, the adapted dried blood spot method) compared to the PCR endpoint. The COPCOV trial was registered with ClinicalTrials.gov; number NCT04303507. Interpretation In this large placebo-controlled, double-blind randomised trial, HCQ and CQ were safe and well tolerated in COVID-19 chemoprevention, and there was evidence of moderate protective benefit in a meta-analysis including this trial and similar RCTs. Trial registration ClinicalTrials.gov NCT04303507; ISRCTN Registry ISRCTN10207947., Author(s): William H. K. Schilling 1,2,*, Mavuto Mukaka 1,2, James J. Callery 1,2, Martin J. Llewelyn 3,4, Cintia V. Cruz 1,2, Mehul Dhorda 1,2, Thatsanun Ngernseng 1, Naomi Waithira 1,2, [...]

Published
2024
Full Text
View/download PDF

4. Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis

Author

Adhikari, Bipin, Alam, Mohammad Shafiul, Anstey, Nicholas M, Assefa, Ashenafi, Baird, J Kevin, Boyd, Sarah C, Chau, Nguyen H, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo U, Ghimire, Prakash, Khan, Wasif A, Ley, Benedikt, Mekuria, Asrat H, Mueller, Ivo, Naadim, Mohammad N, Nosten, Francois, Price, David J, Pukrittayakamee, Sasithon, Rowland, Mark, Sattabongkot, Jetsumon, SuarezKurtz, Guilherme, Sutanto, Inge, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Commons, Robert J, Rajasekhar, Megha, Allen, Elizabeth N, Yilma, Daniel, Chotsiri, Palang, Abreha, Tesfay, Adam, Ishag, Awab, Ghulam Rahim, Barber, Bridget E, Brasil, Larissa W, Chu, Cindy S, Cui, Liwang, Edler, Peta, Gomes, Margarete do Socorro M, Gonzalez‑Ceron, Lilia, Grigg, Matthew J, Hamid, Muzamil Mahdi Abdel, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Leslie, Toby, Longley, Rhea J, Monteiro, Wuelton Marcelo, Pasaribu, Ayodhia Pitaloka, Poespoprodjo, Jeanne Rini, Richmond, Caitlin L, Rijal, Komal Raj, Taylor, Walter R J, Thanh, Pham Vinh, Thriemer, Kamala, Vieira, José Luiz F, White, Nicholas J, Zuluaga-Idarraga, Lina M, Workman, Lesley J, Tarning, Joel, Stepniewska, Kasia, Guerin, Philippe J, Simpson, Julie A, Barnes, Karen I, and Price, Ric N

Published
2024
Full Text
View/download PDF

5. Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo

Author

Onyamboko, Marie A., Olupot-Olupot, Peter, Were, Winifred, Namayanja, Cate, Onyas, Peter, Titin, Harriet, Baseke, Joy, Muhindo, Rita, Kayembe, Daddy K., Ndjowo, Pauline O., Basara, Benjamin B., Okalebo, Charles B., Williams, Thomas N., Uyoga, Sophie, Taya, Chiraporn, Bamisaiye, Adeola, Fanello, Caterina, Maitland, Kathryn, Day, Nicholas P. J., Taylor, Walter R. J., and Mukaka, Mavuto

Published
2023
Full Text
View/download PDF

6. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

Author

Mehdipour, Parinaz, Rajasekhar, Megha, Dini, Saber, Zaloumis, Sophie, Abreha, Tesfay, Adam, Ishag, Awab, Ghulam Rahim, Baird, J. Kevin, Brasil, Larissa W., Chu, Cindy S., Cui, Liwang, Daher, André, do Socorro M Gomes, Margarete, Gonzalez‑Ceron, Lilia, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V. G., Ladeia-Andrade, Simone, Leslie, Toby, Ley, Benedikt, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J., Monteiro, Wuelton Marcelo, Pereira, Dhelio B., Rijal, Komal Raj, Saravu, Kavitha, Sutanto, Inge, Taylor, Walter R. J., Thanh, Pham Vinh, Thriemer, Kamala, Vieira, José Luiz F., White, Nicholas J., Zuluaga-Idarraga, Lina M., Guerin, Philippe J., Price, Ric N., Simpson, Julie A., and Commons, Robert J.

Published
2023
Full Text
View/download PDF

7. The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial

Author

Thriemer, Kamala, Commons, Robert James, Rajasekhar, Megha, Degaga, Tamiru Shibiru, Chand, Krisin, Chau, Nguyen Hoang, Assefa, Ashenafi, Naddim, Mohammad Nader, Pasaribu, Ayodhia Pitaloka, Rahim, Awab Ghulam, Sutanto, Inge, Hien, Tran Tinh, Hailu, Asrat, Hasanzai, Mohammad Anwar, Ekawati, Lenny L., Woyessa, Adugna, Teferi, Tedla, Waithira, Naomi, Taylor, Walter R. J., Ley, Benedikt, Dondorp, Arjen, Baird, J. Kevin, White, Nicholas J., Day, Nicholas P., Price, Ric N., Simpson, Julie A., and von Seidlein, Lorenz

Published
2023
Full Text
View/download PDF

8. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis

Author

Adhikari, Bipin, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Koh, Gavin CKW, Mekuria, Asrat Hailu, Mueller, Ivo, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Price, David J, Sattabongkot, Jetsumon, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Commons, Robert J, Rajasekhar, Megha, Edler, Peta, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Chu, Cindy S, Cui, Liwang, Daher, André, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J, Pereira, Dhelio B, Pasaribu, Ayodhia P, Pukrittayakamee, Sasithon, Rijal, Komal R, Sutanto, Inge, Taylor, Walter R J, Thanh, Pham V, Thriemer, Kamala, Vieira, José Luiz F, Watson, James A, Zuluaga-Idarraga, Lina M, White, Nicholas J, Guerin, Philippe J, Simpson, Julie A, and Price, Ric N

Published
2024
Full Text
View/download PDF

9. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis

Author

Adhikari, Bipin, Alam, Mohammad Shafiul, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Khan, Wasif Ali, Koh, Gavin CKW, Mekuria, Asrat Hailu, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Pasaribu, Ayodhia Pitaloka, Price, David J, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Rajasekhar, Megha, Simpson, Julie A, Ley, Benedikt, Edler, Peta, Chu, Cindy S, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Bancone, Germana, Barber, Bridget E, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Llanos-Cuentas, Alejandro, Pukrittayakamee, Sasithon, Rijal, Komal R, Saravu, Kavitha, Sutanto, Inge, Taylor, Walter R J, Thriemer, Kamala, Watson, James A, Guerin, Philippe J, White, Nicholas J, Price, Ric N, and Commons, Robert J

Published
2024
Full Text
View/download PDF

10. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Author

White, Nicholas J, Schilling, William HK, Phumratanaprapin, Weerapong, Luvira, Viravarn, Callery, James J, Day, Nicholas PJ, Pukrittayakamee, Sasithon, Boyd, Simon, Cruz, Cintia, Dondorp, Arjen M, Taylor, Walter RJ, Watson, James A, Piyaphanee, Watcharapong, Poovorawan, Kittiyod, Ngamprasertchai, Thundon, Siripoon, Tanaya, Hanboonkunupakarn, Borimas, Chotivanich, Kesinee, Jittamala, Podjanee, Imwong, Mallika, Thaipadungpanit, Janjira, Ekkapongpisit, Maneerat, Kruabkontho, Varaporn, Ngernseng, Thatsanun, Tubprasert, Jaruwan, Abdad, Mohammad Yazid, Batty, Elizabeth M, Singh, Shivani, Chotivanich, Vasin, Ruksakul, Wiroj, Sangketchon, Chunlanee, Hanboonkunupakarn, Pongtorn, Sookprome, Sakol, Teixeira, Mauro, Almeida, Pedro J, Aguiar, Renato S, Santos, Franciele, Ashley, Elizabeth, Vongsouvath, Manivanh, Phommasone, Koukeo, Dubot-Pérès, Audrey, Vidhamaly, Sisouphanh, Chingsanoon, Ammala, Bisayher, Sixiong, Chommanam, Danoy, Evans, Terry John, Vidhamaly, Vayouly, Boutthasavong, Latsaniphone, Mayxay, Mayfong, Potaporn, Manus, Srisubat, Attasit, Loharjun, Bootsakorn, Schilling, William H K, Saroj, Manisaree, Tanglakmankhong, Nuttakan, Madmanee, Wanassanan, Kouhathong, Jindarat, Suwannasin, Kanokon, Pagornrat, Watcharee, Piaraksa, Nattaporn, Taylor, Walter R J, Day, Nicholas P J, and Teixeira, Mauro M

Published
2024
Full Text
View/download PDF

11. Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial

Author

Hamaluba, Mainga, van der Pluijm, Rob W, Weya, Joseph, Njuguna, Patricia, Ngama, Mwanajuma, Kalume, Peter, Mwambingu, Gabriel, Ngetsa, Caroline, Wambua, Juliana, Boga, Mwanamvua, Mturi, Neema, Lal, Altaf A, Khuroo, Arshad, Taylor, Walter R J, Gonçalves, Sónia, Miotto, Olivo, Dhorda, Mehul, Mutinda, Brian, Mukaka, Mavuto, Waithira, Naomi, Hoglund, Richard M, Imwong, Mallika, Tarning, Joel, Day, Nicholas P J, White, Nicholas J, Bejon, Philip, and Dondorp, Arjen M

Published
2021
Full Text
View/download PDF

12. Primaquine for uncomplicated Plasmodium vivaxmalaria in children younger than 15 years: a systematic review and individual patient data meta-analysis

Author

Commons, Robert J, Rajasekhar, Megha, Allen, Elizabeth N, Yilma, Daniel, Chotsiri, Palang, Abreha, Tesfay, Adam, Ishag, Awab, Ghulam Rahim, Barber, Bridget E, Brasil, Larissa W, Chu, Cindy S, Cui, Liwang, Edler, Peta, Gomes, Margarete do Socorro M, Gonzalez‑Ceron, Lilia, Grigg, Matthew J, Hamid, Muzamil Mahdi Abdel, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Leslie, Toby, Longley, Rhea J, Monteiro, Wuelton Marcelo, Pasaribu, Ayodhia Pitaloka, Poespoprodjo, Jeanne Rini, Richmond, Caitlin L, Rijal, Komal Raj, Taylor, Walter R J, Thanh, Pham Vinh, Thriemer, Kamala, Vieira, José Luiz F, White, Nicholas J, Zuluaga-Idarraga, Lina M, Workman, Lesley J, Tarning, Joel, Stepniewska, Kasia, Guerin, Philippe J, Simpson, Julie A, Barnes, Karen I, Price, Ric N, Adhikari, Bipin, Alam, Mohammad Shafiul, Anstey, Nicholas M, Assefa, Ashenafi, Baird, J Kevin, Boyd, Sarah C, Chau, Nguyen H, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo U, Ghimire, Prakash, Khan, Wasif A, Ley, Benedikt, Mekuria, Asrat H, Mueller, Ivo, Naadim, Mohammad N, Nosten, Francois, Price, David J, Pukrittayakamee, Sasithon, Rowland, Mark, Sattabongkot, Jetsumon, SuarezKurtz, Guilherme, Sutanto, Inge, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, and Woyessa, Adugna

Abstract

Primaquine, the only widely available treatment to prevent relapsing Plasmodium vivaxmalaria, is produced as 15 mg tablets, and new paediatric formulations are being developed. To inform the optimal primaquine dosing regimen for children, we aimed to determine the efficacy and safety of different primaquine dose strategies in children younger than 15 years.

Published
2024
Full Text
View/download PDF

13. Case Series of Primaquine-Induced Haemolytic Events in Controlled Trials with G6PD Screening

Author

Kosasih, Ayleen, primary, James, Robert, additional, Chau, Nguyen Hoang, additional, Karman, Michelle M., additional, Panggalo, Lydia Visita, additional, Wini, Lyndes, additional, Thanh, Ngo Viet, additional, Obadia, Thomas, additional, Satyagraha, Ari Winasti, additional, Asih, Puji Budi Setia, additional, Syafruddin, Din, additional, Taylor, Walter R. J., additional, Mueller, Ivo, additional, Sutanto, Inge, additional, Karunajeewa, Harin, additional, Pasaribu, Ayodhia Pitaloka, additional, and Baird, J. Kevin, additional

Published
2023
Full Text
View/download PDF

14. Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency

Author

Taylor, Walter R. J., primary, Meagher, Niamh, additional, Ley, Benedikt, additional, Thriemer, Kamala, additional, Bancone, Germana, additional, Satyagraha, Ari, additional, Assefa, Ashenafi, additional, Chand, Krisin, additional, Chau, Nguyen Hoang, additional, Dhorda, Mehul, additional, Degaga, Tamiru S., additional, Ekawati, Lenny L., additional, Hailu, Asrat, additional, Hasanzai, Mohammad Anwar, additional, Naddim, Mohammad Nader, additional, Pasaribu, Ayodhia Pitaloka, additional, Rahim, Awab Ghulam, additional, Sutanto, Inge, additional, Thanh, Ngo Viet, additional, Tuyet-Trinh, Nguyen Thi, additional, Waithira, Naomi, additional, Woyessa, Adugna, additional, Dondorp, Arjen, additional, von Seidlein, Lorenz, additional, Simpson, Julie A., additional, White, Nicholas J., additional, Baird, J. Kevin, additional, Day, Nicholas P., additional, and Price, Ric N., additional

Published
2023
Full Text
View/download PDF

15. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Author

Schilling, William H K, primary, Jittamala, Podjanee, additional, Watson, James A, additional, Boyd, Simon, additional, Luvira, Viravarn, additional, Siripoon, Tanaya, additional, Ngamprasertchai, Thundon, additional, Batty, Elizabeth M, additional, Cruz, Cintia, additional, Callery, James J, additional, Singh, Shivani, additional, Saroj, Manisaree, additional, Kruabkontho, Varaporn, additional, Ngernseng, Thatsanun, additional, Tanglakmankhong, Nuttakan, additional, Tubprasert, Jaruwan, additional, Abdad, Mohammad Yazid, additional, Madmanee, Wanassanan, additional, Kouhathong, Jindarat, additional, Suwannasin, Kanokon, additional, Pagornrat, Watcharee, additional, Piaraksa, Nattaporn, additional, Hanboonkunupakarn, Pongtorn, additional, Hanboonkunupakarn, Borimas, additional, Poovorawan, Kittiyod, additional, Potaporn, Manus, additional, Srisubat, Attasit, additional, Loharjun, Bootsakorn, additional, Taylor, Walter R J, additional, Chotivanich, Vasin, additional, Chotivanich, Kesinee, additional, Imwong, Mallika, additional, Pukrittayakamee, Sasithon, additional, Dondorp, Arjen M, additional, Day, Nicholas P J, additional, Teixeira, Mauro M, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, White, Nicholas J, additional, Schilling, William HK, additional, Day, Nicholas PJ, additional, Taylor, Walter RJ, additional, Thaipadungpanit, Janjira, additional, Ekkapongpisit, Maneerat, additional, Ruksakul, Wiroj, additional, Sangketchon, Chunlanee, additional, Sookprome, Sakol, additional, Teixeira, Mauro, additional, Almeida, Pedro J, additional, Aguiar, Renato S, additional, Santos, Franciele, additional, Ashley, Elizabeth, additional, Vongsouvath, Manivanh, additional, Phommasone, Koukeo, additional, Dubot-Pérès, Audrey, additional, Vidhamaly, Sisouphanh, additional, Chingsanoon, Ammala, additional, Bisayher, Sixiong, additional, Chommanam, Danoy, additional, Evans, Terry John, additional, Vidhamaly, Vayouly, additional, Boutthasavong, Latsaniphone, additional, and Mayxay, Mayfong, additional

Published
2023
Full Text
View/download PDF

16. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis

Author

Commons, Robert J, Simpson, Julie A, Thriemer, Kamala, Humphreys, Georgina S, Abreha, Tesfay, Alemu, Sisay G, Añez, Arletta, Anstey, Nicholas M, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Borghini-Fuhrer, Isabelle, Chu, Cindy S, D'Alessandro, Umberto, Dahal, Prabin, Daher, André, de Vries, Peter J, Erhart, Annette, Gomes, Margarete S M, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Heidari, Aliehsan, Hwang, Jimee, Kager, Piet A, Ketema, Tsige, Khan, Wasif A, Lacerda, Marcus V G, Leslie, Toby, Ley, Benedikt, Lidia, Kartini, Monteiro, Wuelton M, Nosten, Francois, Pereira, Dhelio B, Phan, Giao T, Phyo, Aung P, Rowland, Mark, Saravu, Kavitha, Sibley, Carol H, Siqueira, André M, Stepniewska, Kasia, Sutanto, Inge, Taylor, Walter R J, Thwaites, Guy, Tran, Binh Q, Tran, Hien T, Valecha, Neena, Vieira, José Luiz F, Wangchuk, Sonam, William, Timothy, Woodrow, Charles J, Zuluaga-Idarraga, Lina, Guerin, Philippe J, White, Nicholas J, and Price, Ric N

Published
2018
Full Text
View/download PDF

17. Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)

Author

Jittamala, Podjanee, primary, Schilling, William H K, additional, Watson, James A, additional, Luvira, Viravarn, additional, Siripoon, Tanaya, additional, Ngamprasertchai, Thundon, additional, Almeida, Pedro J, additional, Ekkapongpisit, Maneerat, additional, Cruz, Cintia, additional, Callery, James J, additional, Boyd, Simon, additional, Anunsittichai, Orawan, additional, Hongsuwan, Maliwan, additional, Singhaboot, Yutatirat, additional, Pagornrat, Watcharee, additional, Tuntipaiboontana, Runch, additional, Kruabkontho, Varaporn, additional, Ngernseng, Thatsanun, additional, Tubprasert, Jaruwan, additional, Abdad, Mohammad Yazid, additional, Keayarsa, Srisuda, additional, Madmanee, Wanassanan, additional, Aguiar, Renato S, additional, Santos, Franciele M, additional, Batty, Elizabeth M, additional, Hanboonkunupakarn, Pongtorn, additional, Hanboonkunupakarn, Borimas, additional, Sookprome, Sakol, additional, Poovorawan, Kittiyod, additional, Imwong, Mallika, additional, Taylor, Walter R J, additional, Chotivanich, Vasin, additional, Sangketchon, Chunlanee, additional, Ruksakul, Wiroj, additional, Chotivanich, Kesinee, additional, Pukrittayakamee, Sasithon, additional, Dondorp, Arjen M, additional, Day, Nicholas P J, additional, Teixeira, Mauro M, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, and White, Nicholas J, additional

Published
2023
Full Text
View/download PDF

20. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

Author

Commons, Robert J., Simpson, Julie A., Thriemer, Kamala, Chu, Cindy S., Douglas, Nicholas M., Abreha, Tesfay, Alemu, Sisay G., Añez, Arletta, Anstey, Nicholas M., Aseffa, Abraham, Assefa, Ashenafi, Awab, Ghulam R., Baird, J. Kevin, Barber, Bridget E., Borghini-Fuhrer, Isabelle, D’Alessandro, Umberto, Dahal, Prabin, Daher, André, de Vries, Peter J., Erhart, Annette, Gomes, Margarete S. M., Grigg, Matthew J., Hwang, Jimee, Kager, Piet A., Ketema, Tsige, Khan, Wasif A., Lacerda, Marcus V. G., Leslie, Toby, Ley, Benedikt, Lidia, Kartini, Monteiro, Wuelton M., Pereira, Dhelio B., Phan, Giao T., Phyo, Aung P., Rowland, Mark, Saravu, Kavitha, Sibley, Carol H., Siqueira, André M., Stepniewska, Kasia, Taylor, Walter R. J., Thwaites, Guy, Tran, Binh Q., Hien, Tran T., Vieira, José Luiz F., Wangchuk, Sonam, Watson, James, William, Timothy, Woodrow, Charles J., Nosten, Francois, Guerin, Philippe J., White, Nicholas J., and Price, Ric N.

Published
2019
Full Text
View/download PDF

22. Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies

Author

Chan, Xin Hui S., primary, Chotsiri, Palang, additional, Capel, Rebecca A., additional, Pike, James, additional, Hanboonkunupakarn, Borimas, additional, Lee, Sue J., additional, Hanafiah, Maryam, additional, Win, Yan Naung, additional, Cremer, Maegan A., additional, Kiechel, Jean‐René, additional, Ogutu, Bernhards, additional, Taylor, Walter R. J., additional, Burton, Rebecca‐Ann B., additional, Tarning, Joel, additional, and White, Nicholas J., additional

Published
2022
Full Text
View/download PDF

24. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies

Author

Witkowski, Benoit, Amaratunga, Chanaki, Khim, Nimol, Sreng, Sokunthea, Chim, Pheaktra, Kim, Saorin, Lim, Pharath, Mao, Sivanna, Sopha, Chantha, Sam, Baramey, Anderson, Jennifer M, Duong, Socheat, Chuor, Char Meng, Taylor, Walter R J, Suon, Seila, Mercereau-Puijalon, Odile, Fairhurst, Rick M, and Menard, Didier

Published
2013
Full Text
View/download PDF

25. Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis

Author

Dahal, Prabin, Simpson, Julie Anne, Abdulla, Salim, Achan, Jane, Adam, Ishag, Agarwal, Aarti, Allan, Richard, Anvikar, Anupkumar R., Ashley, Elizabeth A., Bassat, Quique, Borrmann, Steffen, Bousema, Teun, Bukirwa, Hasifa, Carrara, Verena, I, Corsi, Marco, D'Alessandro, Umberto, Davis, Timothy M. E., Deloron, Philippe, Desai, Meghna, Dimbu, Pedro Rafael, Djalle, Djibrine, Djimde, Abdoulaye, Dorsey, Grant, Drakeley, Chris J., Duparc, Stephan, Edstein, Michael D., Espie, Emmanuelle, Faiz, Abul, Falade, Catherine, Fanello, Caterina, Faucher, Jean-Francois, Faye, Babacar, Fortes, Filomeno de Jesus, Gadalla, Nahla B., Gaye, Oumar, Gil, J. Pedro, Gilayeneh, Julius, Greenwood, Brian, Grivoyannis, Anastasia, Hien, Tran Tinh, Hwang, Jimee, Janssens, Bart, Juma, Elizabeth, Kamugisha, Erasmus, Karema, Corine, Karunajeewa, Harin A., Kiechel, Jean R., Kironde, Fred, Kofoed, Poul-Erik, Kremsner, Peter G., Lee, Sue J., Marsh, Kevin, Mårtensson, Andreas, Mayxay, Mayfong, Menan, Herve, Mens, Petra, Mutabingwa, Theonest K., Ndiaye, Jean-Louis, Ngasala, Billy, Noedl, Harald, Nosten, Francois, Offianan, Andre Toure, Ogutu, Bernhards R., Olliaro, Piero L., Ouedraogo, Jean Bosco, Piola, Patrice, Plowe, Christopher, V, Plucinski, Mateusz M., Pratt, Oliver James, Premji, Zulfikarali, Ramharter, Michael, Rogier, Christophe, Vitare, Primum, Rombo, Lars, Rosenthal, Philip J., Sibley, Carol, Sirima, Sodiomon, Smithuis, Frank, Staedke, Sarah G., Sutanto, Inge, Talisuna, Ambrose Otau, Tarning, Joel, Taylor, Walter R. J., Temu, Emmanuel, Thriemer, Kamala, Thuy-Nhien, Nguyen, Udhayakumar, Venkatachalam, Ursing, Johan D., van Herp, Michel, van Lenthe, Marit, van Vugt, Michele, William, Yavo, Winnips, Cornelis, Zaloumis, Sophie, Zongo, Issaka, White, Nick J., Guerin, Philippe J., Stepniewska, Kasia, Price, Ric N., Arinaitwe, Emmanuel, and Group, WorldWide Antimalarial Resistance Network Methodology Study

Subjects
Infectious Medicine, Efficacy, Follow-up, Recrudescence, Artemether, Lumefantrine Drug Combination, Plasmodium falciparum, Infektionsmedicin, Distribution, Artemisinins, Malaria, Antimalarials, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Recurrence, Child, Preschool, Humans, Parasitology, Artemether, Child
Abstract

Background The duration of trial follow-up affects the ability to detect recrudescent infections following anti-malarial treatment. The aim of this study was to explore the proportions of recrudescent parasitaemia as ascribed by genotyping captured at various follow-up time-points in treatment efficacy trials for uncomplicated Plasmodium falciparum malaria. Methods Individual patient data from 83 anti-malarial efficacy studies collated in the WorldWide Antimalarial Resistance Network (WWARN) repository with at least 28 days follow-up were available. The temporal and cumulative distributions of recrudescence were characterized using a Cox regression model with shared frailty on study-sites. Fractional polynomials were used to capture non-linear instantaneous hazard. The area under the density curve (AUC) of the constructed distribution was used to estimate the optimal follow-up period for capturing a P. falciparum malaria recrudescence. Simulation studies were conducted based on the constructed distributions to quantify the absolute overestimation in efficacy due to sub-optimal follow-up. Results Overall, 3703 recurrent infections were detected in 60 studies conducted in Africa (15,512 children aged 48 mg/kg total piperaquine (PIP) dose and 9% [95% CI 0–22%] in those treated with ≤ 48 mg/kg PIP dose. In absolute terms, the simulation study found that trials limited to 28 days follow-up following AL underestimated the risk of recrudescence by a median of 2.8 percentage points compared to day 63 estimates and those limited to 42 days following DP underestimated the risk of recrudescence by a median of 2.0 percentage points compared to day 42 estimates. The analysis was limited by few clinical trials following patients for longer than 42 days (9 out of 83 trials) and the imprecision of PCR genotyping which overcalls recrudescence in areas of higher transmission biasing the later distribution. Conclusions Restricting follow-up of clinical efficacy trials to day 28 for AL and day 42 for DP will miss a proportion of late recrudescent treatment failures but will have a modest impact in derived efficacy. The results highlight that as genotyping methods improve consideration should be given for trials with longer duration of follow-up to detect early indications of emerging drug resistance.

Published
2022

26. Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies.

Author

Chan, Xin Hui S., Chotsiri, Palang, Capel, Rebecca A., Pike, James, Hanboonkunupakarn, Borimas, Lee, Sue J., Hanafiah, Maryam, Win, Yan Naung, Cremer, Maegan A., Kiechel, Jean‐René, Ogutu, Bernhards, Taylor, Walter R. J., Burton, Rebecca‐Ann B., Tarning, Joel, and White, Nicholas J.

Subjects
HEART beat, DIASTOLIC blood pressure, SYSTOLIC blood pressure, MALARIA prevention, KENYANS, BLOOD pressure, ATRIUMS (Architecture)
Abstract

Aims: Amodiaquine is a 4‐aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Amodiaquine can cause bradycardia, hypotension, and electrocardiograph QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized. Methods: We conducted a secondary analysis of a pharmacokinetic study of the cardiac safety of amodiaquine (10 mg base/kg/day over 3 days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Nonlinear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration–effect relationships for vital sign (pulse rate, blood pressure) and electrocardiograph interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations. Results: Amodiaquine and desethylamodiaquine caused concentration‐dependent mean decreases in pulse rate (1.9 beats/min per 100 nmol/L; 95% confidence interval: 1.5–2.4), supine systolic blood pressure (1.7 mmHg per 100 nmol/L; 1.2–2.1), erect systolic blood pressure (1.5 mmHg per 100 nmol/L; 1.0–2.0) and erect diastolic blood pressure (1.4 mmHg per 100 nmol/L; 1.0–1.7). The mean QT interval prolongation was 1.4 ms per 100 nmol/L irrespective of correction factor after adjustment for residual heart rate dependency. There was no significant effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n = 6) and desethylamodiaquine (n = 8) at 3 μmol/L (amodiaquine: 10 ± 2%; desethylamodiaquine: 12 ± 3%) and 10 μmol/L (amodiaquine: 50 ± 7%; desethylamodiaquine: 46 ± 6%) concentrations with no significant difference in potency between the 2 compounds. Conclusion: Amodiaquine and desethylamodiaquine have concentration‐dependent effects on heart rate, blood pressure, and ventricular repolarization. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. In Vivo Parasitological Measures of Artemisinin Susceptibility

Author

Stepniewska, Kasia, Ashley, Elizabeth, Lee, Sue J., Anstey, Nicholas, Barnes, Karen I., Binh, Tran Quang, D'Alessandro, Umberto, Day, Nicholas P. J., de Vries, Peter J., Dorsey, Grant, Guthmann, Jean-Paul, Mayxay, Mayfong, Newton, Paul N., Olliaro, Piero, Osorio, Lyda, Price, Ric N., Rowland, Mark, Smithuis, Frank, Taylor, Walter R. J., Nosten, François, and White, Nicholas J.

Published
2010

35. Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data

Author

Chan, Xin Hui S., primary, Win, Yan Naung, additional, Haeusler, Ilsa L., additional, Tan, Jireh Y., additional, Loganathan, Shanghavie, additional, Saralamba, Sompob, additional, Chan, Shu Kiat S., additional, Ashley, Elizabeth A., additional, Barnes, Karen I., additional, Baiden, Rita, additional, Bassi, Peter U., additional, Djimde, Abdoulaye, additional, Dorsey, Grant, additional, Duparc, Stephan, additional, Hanboonkunupakarn, Borimas, additional, ter Kuile, Feiko O., additional, Lacerda, Marcus V. G., additional, Nasa, Amit, additional, Nosten, François H., additional, Onyeji, Cyprian O., additional, Pukrittayakamee, Sasithon, additional, Siqueira, André M., additional, Tarning, Joel, additional, Taylor, Walter R. J., additional, Valentini, Giovanni, additional, van Vugt, Michèle, additional, Wesche, David, additional, Day, Nicholas P. J., additional, Huang, Christopher L-H, additional, Brugada, Josep, additional, Price, Ric N., additional, and White, Nicholas J., additional

Published
2020
Full Text
View/download PDF

38. Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria : a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

Author

Dahal, Prabin, Simpson, Julie Anne, Abdulla, Salim, Achan, Jane, Adam, Ishag, Agarwal, Aarti, Allan, Richard, Anvikar, Anupkumar R., Arinaitwe, Emmanuel, Ashley, Elizabeth A., Awab, Ghulam Rahim, Bassat, Quique, Bjorkman, Anders, Bompart, Francois, Borrmann, Steffen, Bousema, Teun, Broek, Ingrid, Bukirwa, Hasifa, Carrara, Verena I., Corsi, Marco, Cot, Michel, D'Alessandro, Umberto, Davis, Timothy M. E., de Wit, Marit, Deloron, Philippe, Desai, Meghna, Dimbu, Pedro Rafael, Djalle, Djibrine, Djimde, Abdoulaye, Dorsey, Grant, Doumbo, Ogobara K., Drakeley, Chris J., Duparc, Stephan, Edstein, Michael D., Espie, Emmanuelle, Faiz, Abul, Falade, Catherine, Fanello, Caterina, Faucher, Jean-Francois, Faye, Babacar, Fortes, Filomeno de Jesus, Gadalla, Nahla B., Gaye, Oumar, Gil, J. Pedro, Greenwood, Brian, Grivoyannis, Anastasia, Hamed, Kamal, Hien, Tran Tinh, Hughes, David, Humphreys, Georgina, Hwang, Jimee, Ibrahim, Maman Laminou, Janssens, Bart, Jullien, Vincent, Juma, Elizabeth, Kamugisha, Erasmus, Karema, Corine, Karunajeewa, Harin A., Kiechel, Jean R., Kironde, Fred, Kofoed, Poul-Erik, Kremsner, Peter G., Lameyre, Valerie, Lee, Sue J., Marsh, Kevin, Mårtensson, Andreas, Mayxay, Mayfong, Menan, Herve, Mens, Petra, Mutabingwa, Theonest K., Ndiaye, Jean-Louis, Ngasala, Billy E., Noedl, Harald, Nosten, Francois, Offianan, Andre Toure, Oguike, Mary, Ogutu, Bernhards R., Olliaro, Piero, Ouedraogo, Jean Bosco, Piola, Patrice, Plowe, Christopher V., Plucinski, Mateusz M., Pratt, Oliver James, Premji, Zulfikarali, Ramharter, Michael, Rogier, Christophe, Rombo, Lars, Rosenthal, Philip J., Sawa, Patrick, Schramm, Birgit, Sibley, Carol, Sinou, Veronique, Sirima, Sodiomon, Smithuis, Frank, Staedke, Sarah G., Sutanto, Inge, Talisuna, Ambrose Otau, Tarning, Joel, Taylor, Walter R. J., Temu, Emmanuel, Thriemer, Kamala L., Thuy, Nhien Nguyen, Udhayakumar, Venkatachalam, Ursing, Johan, van Herp, Michel, van Vugt, Michele, Whitty, Christopher, William, Yavo, Winnips, Cornelis, Zongo, Issaka, Guerin, Philippe, Price, Ric N., Stepniewska, Kasia, Dahal, Prabin, Simpson, Julie Anne, Abdulla, Salim, Achan, Jane, Adam, Ishag, Agarwal, Aarti, Allan, Richard, Anvikar, Anupkumar R., Arinaitwe, Emmanuel, Ashley, Elizabeth A., Awab, Ghulam Rahim, Bassat, Quique, Bjorkman, Anders, Bompart, Francois, Borrmann, Steffen, Bousema, Teun, Broek, Ingrid, Bukirwa, Hasifa, Carrara, Verena I., Corsi, Marco, Cot, Michel, D'Alessandro, Umberto, Davis, Timothy M. E., de Wit, Marit, Deloron, Philippe, Desai, Meghna, Dimbu, Pedro Rafael, Djalle, Djibrine, Djimde, Abdoulaye, Dorsey, Grant, Doumbo, Ogobara K., Drakeley, Chris J., Duparc, Stephan, Edstein, Michael D., Espie, Emmanuelle, Faiz, Abul, Falade, Catherine, Fanello, Caterina, Faucher, Jean-Francois, Faye, Babacar, Fortes, Filomeno de Jesus, Gadalla, Nahla B., Gaye, Oumar, Gil, J. Pedro, Greenwood, Brian, Grivoyannis, Anastasia, Hamed, Kamal, Hien, Tran Tinh, Hughes, David, Humphreys, Georgina, Hwang, Jimee, Ibrahim, Maman Laminou, Janssens, Bart, Jullien, Vincent, Juma, Elizabeth, Kamugisha, Erasmus, Karema, Corine, Karunajeewa, Harin A., Kiechel, Jean R., Kironde, Fred, Kofoed, Poul-Erik, Kremsner, Peter G., Lameyre, Valerie, Lee, Sue J., Marsh, Kevin, Mårtensson, Andreas, Mayxay, Mayfong, Menan, Herve, Mens, Petra, Mutabingwa, Theonest K., Ndiaye, Jean-Louis, Ngasala, Billy E., Noedl, Harald, Nosten, Francois, Offianan, Andre Toure, Oguike, Mary, Ogutu, Bernhards R., Olliaro, Piero, Ouedraogo, Jean Bosco, Piola, Patrice, Plowe, Christopher V., Plucinski, Mateusz M., Pratt, Oliver James, Premji, Zulfikarali, Ramharter, Michael, Rogier, Christophe, Rombo, Lars, Rosenthal, Philip J., Sawa, Patrick, Schramm, Birgit, Sibley, Carol, Sinou, Veronique, Sirima, Sodiomon, Smithuis, Frank, Staedke, Sarah G., Sutanto, Inge, Talisuna, Ambrose Otau, Tarning, Joel, Taylor, Walter R. J., Temu, Emmanuel, Thriemer, Kamala L., Thuy, Nhien Nguyen, Udhayakumar, Venkatachalam, Ursing, Johan, van Herp, Michel, van Vugt, Michele, Whitty, Christopher, William, Yavo, Winnips, Cornelis, Zongo, Issaka, Guerin, Philippe, Price, Ric N., and Stepniewska, Kasia

Abstract

Background: Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potentially preclude/pre-empt the detection of subsequent recrudescence of persistent, sub-microscopic primary infections. Methods: Antimalarial studies typically report the risk of recrudescence derived using the Kaplan-Meier (K-M) method, which considers new infections acquired during the follow-up period as censored. Cumulative Incidence Function (CIF) provides an alternative approach for handling new infections, which accounts for them as a competing risk event. The complement of the estimate derived using the K-M method (1 minus K-M), and the CIF were used to derive the risk of recrudescence at the end of the follow-up period using data from studies collated in the WorldWide Antimalarial Resistance Network data repository. Absolute differences in the failure estimates derived using these two methods were quantified. In comparative studies, the equality of two K-M curves was assessed using the log-rank test, and the equality of CIFs using Gray's k-sample test (both at 5% level of significance). Two different regression modelling strategies for recrudescence were considered: cause-specific Cox model and Fine and Gray's sub-distributional hazard model. Results: Data were available from 92 studies (233 treatment arms, 31,379 patients) conducted between 1996 and 2014. At the end of follow-up, the median absolute overestimation in the estimated risk of cumulative recrudescence by using 1 minus K-M approach was 0.04% (interquartile range (IQR): 0.00-0.27%, Range: 0.00-3.60%). The overestimation was correlated positively with the proportion of patients with recrudescence [Pearson's correlation coefficient (rho): 0.38, 95% Confidence Interval (CI) 0.30-0.46] or new infection [rho: 0.43; 95% CI 0.35-0.54]. In three study arms, the point estimates of failure were greater than 10% (the WHO threshold

Published
2019
Full Text
View/download PDF

40. Corrigendum to: Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency

Author

Taylor, Walter R J, primary, Kheng, Sim, primary, Muth, Sinoun, primary, Tor, Pety, primary, Kim, Saorin, primary, Bjorge, Steven, primary, Topps, Narann, primary, Kosal, Khem, primary, Sothea, Khon, primary, Souy, Phum, primary, Char, Chuor Meng, primary, Vanna, Chan, primary, Ly, Po, primary, Khieu, Virak, primary, Christophel, Eva, primary, Kerleguer, Alexandra, primary, Pantaleo, Antonella, primary, Mukaka, Mavuto, primary, Menard, Didier, primary, and Baird, J Kevin, primary

Published
2019
Full Text
View/download PDF

41. Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency

Author

Taylor, Walter R J, primary, Kheng, Sim, additional, Muth, Sinoun, additional, Tor, Pety, additional, Kim, Saorin, additional, Bjorge, Steven, additional, Topps, Narann, additional, Kosal, Khem, additional, Sothea, Khon, additional, Souy, Phum, additional, Char, Chuor Meng, additional, Vanna, Chan, additional, Ly, Po, additional, Khieu, Virak, additional, Christophel, Eva, additional, Kerleguer, Alexandra, additional, Pantaleo, Antonella, additional, Mukaka, Mavuto, additional, Menard, Didier, additional, and Baird, J Kevin, additional

Published
2019
Full Text
View/download PDF

42. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

Author

Taylor, Walter R J, primary, Thriemer, Kamala, additional, von Seidlein, Lorenz, additional, Yuentrakul, Prayoon, additional, Assawariyathipat, Thanawat, additional, Assefa, Ashenafi, additional, Auburn, Sarah, additional, Chand, Krisin, additional, Chau, Nguyen Hoang, additional, Cheah, Phaik Yeong, additional, Dong, Le Thanh, additional, Dhorda, Mehul, additional, Degaga, Tamiru Shibru, additional, Devine, Angela, additional, Ekawati, Lenny L, additional, Fahmi, Fahmi, additional, Hailu, Asrat, additional, Hasanzai, Mohammad Anwar, additional, Hien, Tran Tinh, additional, Khu, Htee, additional, Ley, Benedikt, additional, Lubell, Yoel, additional, Marfurt, Jutta, additional, Mohammad, Hussein, additional, Moore, Kerryn A, additional, Naddim, Mohammad Nader, additional, Pasaribu, Ayodhia Pitaloka, additional, Pasaribu, Syahril, additional, Promnarate, Cholrawee, additional, Rahim, Awab Ghulam, additional, Sirithiranont, Pasathron, additional, Solomon, Hiwot, additional, Sudoyo, Herawati, additional, Sutanto, Inge, additional, Thanh, Ngo Viet, additional, Tuyet-Trinh, Nguyen Thi, additional, Waithira, Naomi, additional, Woyessa, Adugna, additional, Yamin, Fazal Yamin, additional, Dondorp, Arjen, additional, Simpson, Julie A, additional, Baird, J Kevin, additional, White, Nicholas J, additional, Day, Nicholas P, additional, and Price, Ric N, additional

Published
2019
Full Text
View/download PDF

44. In Vivo Parasitological Measures of Artemisinin Susceptibility

Author

Stepniewska, Kasia, Ashley, Elizabeth, Lee, Sue J., Anstey, Nicholas, Barnes, Karen I., Binh, Tran Quang, D'Alessandro, Umberto, Day, Nicholas P. J., de Vries, Peter J., Dorsey, Grant, Guthmann, Jean-Paul, Mayxay, Mayfong, Newton, Paul N., Olliaro, Piero, Osorio, Lyda, Price, Ric N., Rowland, Mark, Smithuis, Frank, Taylor, Walter R. J., Nosten, François, White, Nicholas J., Stepniewska, Kasia, Ashley, Elizabeth, Lee, Sue J., Anstey, Nicholas, Barnes, Karen I., Binh, Tran Quang, D'Alessandro, Umberto, Day, Nicholas P. J., de Vries, Peter J., Dorsey, Grant, Guthmann, Jean-Paul, Mayxay, Mayfong, Newton, Paul N., Olliaro, Piero, Osorio, Lyda, Price, Ric N., Rowland, Mark, Smithuis, Frank, Taylor, Walter R. J., Nosten, François, and White, Nicholas J.

Abstract

Parasite clearance data from 18,699 patients with falciparum malaria treated with an artemisinin derivative in areas of low (n = 14,539), moderate (n = 2077), and high (n = 2083) levels of malaria transmission across the world were analyzed to determine the factors that affect clearance rates and identify a simple in vivo screening measure for artemisinin resistance. The main factor affecting parasite clearance time was parasite density on admission. Clearance rates were faster in high-transmission settings and with more effective partner drugs in artemisinin-based combination treatments (ACTs). The result of the malaria blood smear on day 3 (72 h) was a good predictor of subsequent treatment failure and provides a simple screening measure for artemisinin resistance. Artemisinin resistance is highly unlikely if the proportion of patients with parasite densities of <100,000 parasites/µL given the currently recommended 3-day ACT who have a positive smear result on day 3 is <3%; that is, for n patients the observed number with a positive smear result on day 3 does not exceed (n + 60)/24

Published
2017

45. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data

Author

Abdulla, Salim, Adam, Ishag, Adjei, George O., Adjuik, Martin A., Alemayehu, Bereket, Allan, Richard, Arinaitwe, Emmanuel, Ashley, Elizabeth A., Ba, Mamadou S., Barennes, Hubert, Barnes, Karen I., Bassat, Quique, Baudin, Elisabeth, Berens-Riha, Nicole, Bjoerkman, Anders, Bompart, Francois, Bonnet, Maryline, Borrmann, Steffen, Bousema, Teun, Brasseur, Philippe, Bukirwa, Hasifa, Checchi, Francesco, Dahal, Prabin, D'Alessandro, Umberto, Desai, Meghna, Dicko, Alassane, Djimde, Abdoulaye A., Dorsey, Grant, Doumbo, Ogobara K., Drakeley, Chris J., Duparc, Stephan, Eshetu, Teferi, Espie, Emmanuelle, Etard, Jean-Francois, Faiz, Abul M., Falade, Catherine O., Fanello, Caterina I., Faucher, Jean-Francois, Faye, Babacar, Faye, Oumar, Filler, Scott, Flegg, Jennifer A., Fofana, Bakary, Fogg, Carole, Gadalla, Nahla B., Gaye, Oumar, Genton, Blaise, Gething, Peter W., Gil, Jose P., Gonzalez, Raquel, Grandesso, Francesco, Greenhouse, Bryan, Greenwood, Brian, Grivoyannis, Anastasia, Guerin, Philippe J., Guthmann, Jean-Paul, Hamed, Kamal, Hamour, Sally, Hay, Simon I., Hodel, Eva Maria, Humphreys, Georgina S., Hwang, Jimee, Ibrahim, Maman L., Jima, Daddi, Jones, Joel J., Jullien, Vincent, Juma, Elizabeth, Kachur, Patrick S., Kager, Piet A., Kamugisha, Erasmus, Kamya, Moses R., Karema, Corine, Kayentao, Kassoum, Kiechel, Jean-Rene, Kironde, Fred, Kofoed, Poul-Erik, Kremsner, Peter G., Krishna, Sanjeev, Lameyre, Valerie, Lell, Bertrand, Lima, Angeles, Makanga, Michael, Malik, ElFatih M., Marsh, Kevin, Martensson, Andreas, Massougbodji, Achille, Menan, Herve, Menard, Didier, Menendez, Clara, Mens, Petra F., Meremikwu, Martin, Moreira, Clarissa, Nabasumba, Carolyn, Nambozi, Michael, Ndiaye, Jean-Louis, Ngasala, Billy E., Nikiema, Frederic, Nsanzabana, Christian, Ntoumi, Francine, Oguike, Mary, Ogutu, Bernhards R., Olliaro, Piero, Omar, Sabah A., Ouedraogo, Jean-Bosco, Owusu-Agyei, Seth, Penali, Louis K., Pene, Mbaye, Peshu, Judy, Piola, Patrice, Plowe, Christopher V., Premji, Zul, Price, Ric N., Randrianarivelojosia, Milijaona, Rombo, Lars, Roper, Cally, Rosenthal, Philip J., Sagara, Issaka, Same-Ekobo, Albert, Sawa, Patrick, Schallig, Henk D. F. H., Schramm, Birgit, Seck, Amadou, Shekalaghe, Seif A., Sibley, Carol H., Sinou, Vronique, Sirima, Sodiomon B., Som, Fabrice A., Sow, Doudou, Staedke, Sarah G., Stepniewska, Kasia, Sutherland, Colin J., Swarthout, Todd D., Sylla, Khadime, Talisuna, Ambrose O., Taylor, Walter R. J., Temu, Emmanuel A., Thwing, Julie I., Tine, Roger C. K., Tinto, Halidou, Tommasini, Silva, Toure, Offianan A., Ursing, Johan, Vaillant, Michel T., Valentini, Giovanni, Van den Broek, Ingrid, Van Vugt, Michele, Ward, Stephen A., Winstanley, Peter A., Yavo, William, Yeka, Adoke, Zolia, Yah M., Zongo, Issaka, and WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group

Subjects
parasitic diseases
Abstract

BACKGROUND: Artemisinin-resistant Plasmodium falciparum has emerged in the Greater Mekong sub-region and poses a major global public health threat. Slow parasite clearance is a key clinical manifestation of reduced susceptibility to artemisinin. This study was designed to establish the baseline values for clearance in patients from Sub-Saharan African countries with uncomplicated malaria treated with artemisinin-based combination therapies (ACTs). METHODS: A literature review in PubMed was conducted in March 2013 to identify all prospective clinical trials (uncontrolled trials, controlled trials and randomized controlled trials), including ACTs conducted in Sub-Saharan Africa, between 1960 and 2012. Individual patient data from these studies were shared with the WorldWide Antimalarial Resistance Network (WWARN) and pooled using an a priori statistical analytical plan. Factors affecting early parasitological response were investigated using logistic regression with study sites fitted as a random effect. The risk of bias in included studies was evaluated based on study design, methodology and missing data. RESULTS: In total, 29,493 patients from 84 clinical trials were included in the analysis, treated with artemether-lumefantrine (n = 13,664), artesunate-amodiaquine (n = 11,337) and dihydroartemisinin-piperaquine (n = 4,492). The overall parasite clearance rate was rapid. The parasite positivity rate (PPR) decreased from 59.7 % (95 % CI: 54.5-64.9) on day 1 to 6.7 % (95 % CI: 4.8-8.7) on day 2 and 0.9 % (95 % CI: 0.5-1.2) on day 3. The 95th percentile of observed day 3 PPR was 5.3 %. Independent risk factors predictive of day 3 positivity were: high baseline parasitaemia (adjusted odds ratio (AOR) = 1.16 (95 % CI: 1.08-1.25); per 2-fold increase in parasite density, P 37.5 °C) (AOR = 1.50 (95 % CI: 1.06-2.13), P = 0.022); severe anaemia (AOR = 2.04 (95 % CI: 1.21-3.44), P = 0.008); areas of low/moderate transmission setting (AOR = 2.71 (95 % CI: 1.38-5.36), P = 0.004); and treatment with the loose formulation of artesunate-amodiaquine (AOR = 2.27 (95 % CI: 1.14-4.51), P = 0.020, compared to dihydroartemisinin-piperaquine). CONCLUSIONS: The three ACTs assessed in this analysis continue to achieve rapid early parasitological clearance across the sites assessed in Sub-Saharan Africa. A threshold of 5 % day 3 parasite positivity from a minimum sample size of 50 patients provides a more sensitive benchmark in Sub-Saharan Africa compared to the current recommended threshold of 10 % to trigger further investigation of artemisinin susceptibility.

Published
2015

47. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria : a meta-analysis of individual patient data

Author

Adjuik, Martin A., Allan, Richard, Anvikar, Anupkumar R., Ashley, Elizabeth A., Ba, Mamadou S., Barennes, Hubert, Barnes, Karen I., Bassat, Quique, Baudin, Elisabeth, Bjorkman, Anders, Bompart, Francois, Bonnet, Maryline, Borrmann, Steffen, Brasseur, Philippe, Bukirwa, Hasifa, Checchi, Francesco, Cot, Michel, Dahal, Prabin, D'Alessandro, Umberto, Deloron, Philippe, Desai, Meghna, Diap, Graciela, Djimde, Abdoulaye A., Dorsey, Grant, Doumbo, Ogobara K., Espie, Emmanuelle, Etard, Jean-Francois, Fanello, Caterina I., Faucher, Jean-Francois, Faye, Babacar, Flegg, Jennifer A., Gaye, Oumar, Gething, Peter W., Gonzalez, Raquel, Grandesso, Francesco, Guerin, Philippe J., Guthmann, Jean-Paul, Hamour, Sally, Hasugian, Armedy Ronny, Hay, Simon I., Humphreys, Georgina S., Jullien, Vincent, Juma, Elizabeth, Kamya, Moses R., Karema, Corine, Kiechel, Jean R., Kremsner, Peter G., Krishna, Sanjeev, Lameyre, Valerie, Ibrahim, Laminou M., Lee, Sue J., Lell, Bertrand, Martensson, Andreas, Massougbodji, Achille, Menan, Herve, Menard, Didier, Menendez, Clara, Meremikwu, Martin, Moreira, Clarissa, Nabasumba, Carolyn, Nambozi, Michael, Ndiaye, Jean-Louis, Nikiema, Frederic, Nsanzabana, Christian, Ntoumi, Francine, Ogutu, Bernhards R., Olliaro, Piero, Osorio, Lyda, Ouedraogo, Jean-Bosco, Penali, Louis K., Pene, Mbaye, Pinoges, Loretxu, Piola, Patrice, Price, Ric N., Roper, Cally, Rosenthal, Philip J., Rwagacondo, Claude Emile, Same-Ekobo, Albert, Schramm, Birgit, Seck, Amadou, Sharma, Bhawna, Sibley, Carol Hopkins, Sinou, Veronique, Sirima, Sodiomon B., Smith, Jeffery J., Smithuis, Frank, Some, Fabrice A., Sow, Doudou, Staedke, Sarah G., Stepniewska, Kasia, Swarthout, Todd D., Sylla, Khadime, Talisuna, Ambrose O., Tarning, Joel, Taylor, Walter R. J., Temu, Emmanuel A., Thwing, Julie I., Tjitra, Emiliana, Tine, Roger C. K., Tinto, Halidou, Vaillant, Michel T., Valecha, Neena, Van den Broek, Ingrid, White, Nicholas J., Yeka, Adoke, Zongo, Issaka, Adjuik, Martin A., Allan, Richard, Anvikar, Anupkumar R., Ashley, Elizabeth A., Ba, Mamadou S., Barennes, Hubert, Barnes, Karen I., Bassat, Quique, Baudin, Elisabeth, Bjorkman, Anders, Bompart, Francois, Bonnet, Maryline, Borrmann, Steffen, Brasseur, Philippe, Bukirwa, Hasifa, Checchi, Francesco, Cot, Michel, Dahal, Prabin, D'Alessandro, Umberto, Deloron, Philippe, Desai, Meghna, Diap, Graciela, Djimde, Abdoulaye A., Dorsey, Grant, Doumbo, Ogobara K., Espie, Emmanuelle, Etard, Jean-Francois, Fanello, Caterina I., Faucher, Jean-Francois, Faye, Babacar, Flegg, Jennifer A., Gaye, Oumar, Gething, Peter W., Gonzalez, Raquel, Grandesso, Francesco, Guerin, Philippe J., Guthmann, Jean-Paul, Hamour, Sally, Hasugian, Armedy Ronny, Hay, Simon I., Humphreys, Georgina S., Jullien, Vincent, Juma, Elizabeth, Kamya, Moses R., Karema, Corine, Kiechel, Jean R., Kremsner, Peter G., Krishna, Sanjeev, Lameyre, Valerie, Ibrahim, Laminou M., Lee, Sue J., Lell, Bertrand, Martensson, Andreas, Massougbodji, Achille, Menan, Herve, Menard, Didier, Menendez, Clara, Meremikwu, Martin, Moreira, Clarissa, Nabasumba, Carolyn, Nambozi, Michael, Ndiaye, Jean-Louis, Nikiema, Frederic, Nsanzabana, Christian, Ntoumi, Francine, Ogutu, Bernhards R., Olliaro, Piero, Osorio, Lyda, Ouedraogo, Jean-Bosco, Penali, Louis K., Pene, Mbaye, Pinoges, Loretxu, Piola, Patrice, Price, Ric N., Roper, Cally, Rosenthal, Philip J., Rwagacondo, Claude Emile, Same-Ekobo, Albert, Schramm, Birgit, Seck, Amadou, Sharma, Bhawna, Sibley, Carol Hopkins, Sinou, Veronique, Sirima, Sodiomon B., Smith, Jeffery J., Smithuis, Frank, Some, Fabrice A., Sow, Doudou, Staedke, Sarah G., Stepniewska, Kasia, Swarthout, Todd D., Sylla, Khadime, Talisuna, Ambrose O., Tarning, Joel, Taylor, Walter R. J., Temu, Emmanuel A., Thwing, Julie I., Tjitra, Emiliana, Tine, Roger C. K., Tinto, Halidou, Vaillant, Michel T., Valecha, Neena, Van den Broek, Ingrid, White, Nicholas J., Yeka, Adoke, and Zongo, Issaka

Abstract

Background: Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa. We investigated the impact of different dosing strategies on the efficacy of this combination for the treatment of falciparum malaria. Methods: Individual patient data from AS-AQ clinical trials were pooled using the WorldWide Antimalarial Resistance Network (WWARN) standardised methodology. Risk factors for treatment failure were identified using a Cox regression model with shared frailty across study sites. Results: Forty-three studies representing 9,106 treatments from 1999-2012 were included in the analysis; 4,138 (45.4%) treatments were with a fixed dose combination with an AQ target dose of 30 mg/kg (FDC), 1,293 (14.2%) with a non-fixed dose combination with an AQ target dose of 25 mg/kg (loose NFDC-25), 2,418 (26.6%) with a non-fixed dose combination with an AQ target dose of 30 mg/kg (loose NFDC-30), and the remaining 1,257 (13.8%) with a co-blistered non-fixed dose combination with an AQ target dose of 30 mg/kg (co-blistered NFDC). The median dose of AQ administered was 32.1 mg/kg [IQR: 25.9-38.2], the highest dose being administered to patients treated with co-blistered NFDC (median = 35.3 mg/kg [IQR: 30.6-43.7]) and the lowest to those treated with loose NFDC-25 (median = 25.0 mg/kg [IQR: 22.7-25.0]). Patients treated with FDC received a median dose of 32.4 mg/kg [IQR: 27-39.0]. After adjusting for reinfections, the corrected antimalarial efficacy on day 28 after treatment was similar for co-blistered NFDC (97.9% [95% confidence interval (CI): 97.0-98.8%]) and FDC (98.1% [95% CI: 97.6%-98.5%]; P = 0.799), but significantly lower for the loose NFDC-25 (93.4% [95% CI: 91.9%-94.9%]), and loose NFDC-30 (95.0% [95% CI: 94.1%-95.9%]) (P < 0.001 for all comparisons). After controlling for age, AQ dose, baseline parasitemia and region; treatment with loose NFDC-25 was associated

Published
2015
Full Text
View/download PDF

48. Short-course primaquine for the radical cure of Plasmodium vivaxmalaria: a multicentre, randomised, placebo-controlled non-inferiority trial

Author

Taylor, Walter R J, Thriemer, Kamala, von Seidlein, Lorenz, Yuentrakul, Prayoon, Assawariyathipat, Thanawat, Assefa, Ashenafi, Auburn, Sarah, Chand, Krisin, Chau, Nguyen Hoang, Cheah, Phaik Yeong, Dong, Le Thanh, Dhorda, Mehul, Degaga, Tamiru Shibru, Devine, Angela, Ekawati, Lenny L, Fahmi, Fahmi, Hailu, Asrat, Hasanzai, Mohammad Anwar, Hien, Tran Tinh, Khu, Htee, Ley, Benedikt, Lubell, Yoel, Marfurt, Jutta, Mohammad, Hussein, Moore, Kerryn A, Naddim, Mohammad Nader, Pasaribu, Ayodhia Pitaloka, Pasaribu, Syahril, Promnarate, Cholrawee, Rahim, Awab Ghulam, Sirithiranont, Pasathron, Solomon, Hiwot, Sudoyo, Herawati, Sutanto, Inge, Thanh, Ngo Viet, Tuyet-Trinh, Nguyen Thi, Waithira, Naomi, Woyessa, Adugna, Yamin, Fazal Yamin, Dondorp, Arjen, Simpson, Julie A, Baird, J Kevin, White, Nicholas J, Day, Nicholas P, and Price, Ric N

Abstract

Primaquine is the only widely used drug that prevents Plasmodium vivaxmalaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria.

Published
2019
Full Text
View/download PDF

49. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency

Author

Kheng, Sim, primary, Muth, Sinoun, additional, Taylor, Walter R. J., additional, Tops, Narann, additional, Kosal, Khem, additional, Sothea, Khon, additional, Souy, Phum, additional, Kim, Saorin, additional, Char, Chuor Meng, additional, Vanna, Chan, additional, Ly, Po, additional, Ringwald, Pascal, additional, Khieu, Virak, additional, Kerleguer, Alexandra, additional, Tor, Pety, additional, Baird, John K., additional, Bjorge, Steven, additional, Menard, Didier, additional, and Christophel, Eva, additional

Published
2015
Full Text
View/download PDF

50. Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment

Author

Leang, Rithea, primary, Taylor, Walter R. J., additional, Bouth, Denis Mey, additional, Song, Lijiang, additional, Tarning, Joel, additional, Char, Meng Chuor, additional, Kim, Saorin, additional, Witkowski, Benoit, additional, Duru, Valentine, additional, Domergue, Anais, additional, Khim, Nimol, additional, Ringwald, Pascal, additional, and Menard, Didier, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results